Chronic Heart Disease
8
0
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
13%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Pre-Symptomatic Detection of Impending Decompensation in Heart Failure Through Voice Data
Dyspnea Assessment in Hemodialysis Patients
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
Relationships and Differences Analysis in Heart Failure
Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System
Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System
Integral Clinical Plan Shared With or Without Telemonitoring of Constants in Patient With Chronic Diseases
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus